肺癌是我国及世界范围内发病率和死亡率最高的恶性肿瘤之一，非小细胞肺癌（NSCLC）约占肺癌的 85%，1/3 的患者在确诊时已为局部晚期 NSCLC，5 年生存率仅 13% ~ 16%。其中，N2 期肺癌患者预后更差，手术切除后 3 年生存率仅 9% ...

Health Canada has approved MSD's anti-programmed cell death protein 1 (PD-1) therapy Keytruda for treating adults with resectable stage II, IIIA or IIIB non-small cell lung carcinoma (NSCLC) in ...

IIIA or IIIB non-small cell lung cancer (NSCLC). The approval marks the first indication for the anti-programmed cell death protein 1 (PD-1) therapy in the earlier stages of this NSCLC in China ...